PL3068491T3 - Pochodna kwasu 7-aminocefalosporanowego jako inhibitor aktywności IL-15 oraz IL-2 - Google Patents

Pochodna kwasu 7-aminocefalosporanowego jako inhibitor aktywności IL-15 oraz IL-2

Info

Publication number
PL3068491T3
PL3068491T3 PL14799527T PL14799527T PL3068491T3 PL 3068491 T3 PL3068491 T3 PL 3068491T3 PL 14799527 T PL14799527 T PL 14799527T PL 14799527 T PL14799527 T PL 14799527T PL 3068491 T3 PL3068491 T3 PL 3068491T3
Authority
PL
Poland
Prior art keywords
inhibitor
activity
acid derivative
aminocephalosporanic acid
aminocephalosporanic
Prior art date
Application number
PL14799527T
Other languages
English (en)
Inventor
Katarzyna KOZIAK
Barbara ŻYŻYŃSKA-GRANICA
Sławomir FILIPEK
Szymon NIEWIECZERZAŁ
Bartosz TRZASKOWSKI
Oliwia Zegrocka-Stendel
Małgorzata DUTKIEWICZ
Piotr KRZECZYŃSKI
Elżbieta KACZMAREK
Magdalena Winiarska
Original Assignee
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny filed Critical Warszawski Uniwersytet Medyczny
Publication of PL3068491T3 publication Critical patent/PL3068491T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14799527T 2013-09-30 2014-09-29 Pochodna kwasu 7-aminocefalosporanowego jako inhibitor aktywności IL-15 oraz IL-2 PL3068491T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL40550613A PL405506A1 (pl) 2013-09-30 2013-09-30 Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2
PCT/IB2014/001940 WO2015044762A1 (en) 2013-09-30 2014-09-29 7-aminocephalosporanic acid derivative as inhibitor of il-15 and il-2 activity
EP14799527.8A EP3068491B1 (en) 2013-09-30 2014-09-29 7-aminocephalosporanic acid derivative as inhibitor of il-15 and il-2 activity

Publications (1)

Publication Number Publication Date
PL3068491T3 true PL3068491T3 (pl) 2019-12-31

Family

ID=51903949

Family Applications (3)

Application Number Title Priority Date Filing Date
PL40550613A PL405506A1 (pl) 2013-09-30 2013-09-30 Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2
PL14799527T PL3068491T3 (pl) 2013-09-30 2014-09-29 Pochodna kwasu 7-aminocefalosporanowego jako inhibitor aktywności IL-15 oraz IL-2
PL417879A PL235635B1 (pl) 2013-09-30 2014-09-29 Pochodna kwasu 7-aminocefalosporanowego-cefazolina oraz zawierający ją preparat farmaceutyczny do zastosowania w leczeniu i zapobieganiu chorób, u podłoża których leży nadmierna produkcja interleukiny 15 oraz interleukiny 2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL40550613A PL405506A1 (pl) 2013-09-30 2013-09-30 Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL417879A PL235635B1 (pl) 2013-09-30 2014-09-29 Pochodna kwasu 7-aminocefalosporanowego-cefazolina oraz zawierający ją preparat farmaceutyczny do zastosowania w leczeniu i zapobieganiu chorób, u podłoża których leży nadmierna produkcja interleukiny 15 oraz interleukiny 2

Country Status (9)

Country Link
US (2) US20160235762A1 (pl)
EP (1) EP3068491B1 (pl)
AU (2) AU2014326355B2 (pl)
CA (1) CA2925652A1 (pl)
DK (1) DK3068491T3 (pl)
ES (1) ES2747635T3 (pl)
PL (3) PL405506A1 (pl)
PT (1) PT3068491T (pl)
WO (1) WO2015044762A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3124016T3 (da) 2015-07-31 2019-12-09 Univ Warszawski Medyczny Antipsoriatisk emulsionspræparat omfattende cefazolin
US11278505B2 (en) 2017-04-24 2022-03-22 University Of Massachusetts Diagnosis and treatment of vitiligo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891370A (en) 1981-12-14 1990-01-02 Merck & Co., Inc. Cephalosporin derivatives as anti-inflammatory agents
CN1247057A (zh) * 1999-06-07 2000-03-15 李桂华 口腔保洁剂的配制方法
CA2490062A1 (en) * 2002-05-23 2003-12-04 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
JP2007131535A (ja) * 2003-12-26 2007-05-31 Tokai Univ 蛋白修飾物生成抑制剤
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
WO2007065167A1 (en) * 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
CU23716A1 (es) 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15

Also Published As

Publication number Publication date
AU2014326355A1 (en) 2016-04-28
DK3068491T3 (da) 2019-10-14
WO2015044762A1 (en) 2015-04-02
PT3068491T (pt) 2019-10-24
AU2019236714A1 (en) 2019-10-17
EP3068491A1 (en) 2016-09-21
AU2019236714B2 (en) 2020-10-15
US11452728B2 (en) 2022-09-27
PL417879A1 (pl) 2017-02-13
EP3068491B1 (en) 2019-07-03
US20170319593A1 (en) 2017-11-09
PL235635B1 (pl) 2020-09-21
AU2014326355B2 (en) 2019-06-27
CA2925652A1 (en) 2015-04-02
PL405506A1 (pl) 2015-04-13
ES2747635T3 (es) 2020-03-11
US20160235762A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
EP2903613A4 (en) INHIBITORS OF IRAQ4 ACTIVITY
EP2903617A4 (en) INHIBITORS OF IRAQ4 ACTIVITY
SI3080100T1 (sl) Inhibitorji lizin specifične demetilaze-1
HK1219271A1 (zh) 作爲 抑制劑的化合物和組合物
AP2014007900A0 (en) Inhibitors of beta-secretase
AP2014007679A0 (en) Use of inhibitors of the activity or function of P13K
HRP20181291T1 (hr) Heterobicikloarilni inhibitori rorc2 i njihova upotreba
IL272301B (en) Benzamide and nicotinamide compounds and methods of using them
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
IL240763B (en) The halopyrazoles as thrombin inhibitors
EP2906041A4 (en) COMPOSITIONS AND METHODS OF USING INAPPETENCE COMPOUND
SG11201603506PA (en) Treatment of damaged nerve with pten inhibitor
HK1220125A1 (zh) 拉喹莫德的透皮配方
PL3068491T3 (pl) Pochodna kwasu 7-aminocefalosporanowego jako inhibitor aktywności IL-15 oraz IL-2
GB201312311D0 (en) Uses of enzyme inhibitors
GB2523616B (en) Use of quinolinone compound as hCBS enzyme inhibitor
EP3016646A4 (en) NOVEL FORMULATIONS OF FACTOR VIIa INHIBITORS AND UTILITY
GB201322036D0 (en) New therapeutic uses of enzyme inhibitors
GB201310488D0 (en) New therapeutic uses of enzyme inhibitors